10月29日，步长制药（证券代码：603858）公告，公司的控股子公司泸州步长与越南公司Helios Pharmaceutical Company Limited及早安国际贸易有限公司签署了《经销、营销服务和代理协议》。根据协议，泸州步长授权Helios在越南区域内独家营销和经销注射用Efparepoetin alfa（注射用依派促红素a），该药品适用于治疗成人透析患者因慢性肾脏病引起的贫血，目前 ...

Development follows company’s ₹350-crore investment in India to expand research, manufacturing, and sustainability-led ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

This article originally appeared on MyCentralJersey.com: Global pharmaceutical firm chooses Bridgewater for new corporate ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...

Key Points Added 4,306,363 Teva shares, an estimated $75.64 million trade based on the average quarterly price for Q3 2025 Transaction represents a 0.68% increase in reportable U.S. equity assets ...

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet ...